| Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease B Finan, C Clemmensen, Z Zhu, K Stemmer, K Gauthier, L Müller, ... Cell 167 (3), 843-857. e14, 2016 | 195 | 2016 |
| GLP-1/glucagon receptor co-agonism for treatment of obesity MA Sánchez-Garrido, SJ Brandt, C Clemmensen, TD Müller, RD DiMarchi, ... Diabetologia 60, 1851-1861, 2017 | 167 | 2017 |
| Gut hormone polyagonists for the treatment of type 2 diabetes SJ Brandt, A Götz, MH Tschöp, TD Müller Peptides 100, 190-201, 2018 | 119 | 2018 |
| Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology SJ Brandt, TD Müller, RD DiMarchi, MH Tschöp, K Stemmer Journal of internal medicine 284 (6), 581-602, 2018 | 49 | 2018 |
| Are peptide conjugates the golden therapy against obesity? SJ Brandt, M Kleinert, MH Tschöp, TD Müller Journal of Endocrinology 238 (2), R109-R119, 2018 | 30 | 2018 |
| Redox potentials of Ti (IV) and Fe (III) complexes provide insights into titanium biodistribution mechanisms CJP Siburt, EM Lin, SJ Brandt, AD Tinoco, AM Valentine, AL Crumbliss Journal of inorganic biochemistry 104 (9), 1006-1009, 2010 | 25 | 2010 |
| Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity SJ Brandt, JP Mayer, J Ford, VM Gelfanov, RD DiMarchi Peptides 100, 18-23, 2018 | 6 | 2018 |
| Metal-complex structures and redox potentials used to construct LFER CJP Siburt, EM Lin, SJ Brandt, AD Tinoco, AM Valentine, AL Crumbliss | | |